Adaptive Biotech Welcomes Charles Sang As Senior Vice President Of Diagnostics
SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces the appointment of Charles Sang to Senior Vice President, Diagnostics. Mr. Sang will be pivotal in leading the Company’s diagnostics business strategy for the clonoSEQ® Process which provides ultra-sensitive detection of minimal residual disease (MRD) in patients with lymphoid cancers, and may allow for earlier intervention for patients who may relapse. Tom Willis, PhD, will be transitioning to an advisory role pertaining to the Company’s continued validation efforts for the clonoSEQ Process while also remaining as an active member on the Company’s board.
“Charles brings a wealth of solid diagnostics and therapeutic experience in Hematology/Oncology and rare diseases to Adaptive’s growing commercial business,” said Chad Robins, President, Chief Executive Officer and Co-founder of Adaptive Biotechnologies. “I am pleased to welcome Charles to our Executive Team and look forward to working together to make the clonoSEQ Process the most clinically validated, market-leading next generation sequencing test for MRD detection.”
At Adaptive, Mr. Sang will initially be focused on securing clinical guidelines and reimbursement decisions while supporting regulatory approval efforts for the clonoSEQ Process globally. He was most recently the Vice President of Global Diagnostics for Nanostring Technologies, Inc. and led their North American and Global commercial efforts for a new product class of decentralized genomic assays in solid and liquid tumors, including the launch of Prosigna®, the company’s breast cancer prognostic gene signature assay. Mr. Sang has more than 20 years of Hematology/Oncology expertise, including the global launch of products in highly specialized markets while ensuring their reimbursement. Mr. Sang has also held commercial leadership positions at Seattle Genetics and Enzon Pharmaceuticals.
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit adaptivebiotech.com.
About Minimal Residual Disease
Minimal residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells are present at levels undetectable by traditional microscopic examination (also called morphologic examination) of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as the next generation sequencing utilized by Adaptive’s clonoSEQ MRD Test, are needed for reliable detection of very low levels of MRD. Learn more at knowMRD.com.
About the clonoSEQ® Process
Adaptive’s clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than the other methods of MRD detection, such as ASO-PCR and flow cytometry.
Contacts
Adaptive Biotechnologies
April Falcone, 206-939-3835
media@adaptivebiotech.com
“Charles brings a wealth of solid diagnostics and therapeutic experience in Hematology/Oncology and rare diseases to Adaptive’s growing commercial business,” said Chad Robins, President, Chief Executive Officer and Co-founder of Adaptive Biotechnologies. “I am pleased to welcome Charles to our Executive Team and look forward to working together to make the clonoSEQ Process the most clinically validated, market-leading next generation sequencing test for MRD detection.”
At Adaptive, Mr. Sang will initially be focused on securing clinical guidelines and reimbursement decisions while supporting regulatory approval efforts for the clonoSEQ Process globally. He was most recently the Vice President of Global Diagnostics for Nanostring Technologies, Inc. and led their North American and Global commercial efforts for a new product class of decentralized genomic assays in solid and liquid tumors, including the launch of Prosigna®, the company’s breast cancer prognostic gene signature assay. Mr. Sang has more than 20 years of Hematology/Oncology expertise, including the global launch of products in highly specialized markets while ensuring their reimbursement. Mr. Sang has also held commercial leadership positions at Seattle Genetics and Enzon Pharmaceuticals.
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit adaptivebiotech.com.
About Minimal Residual Disease
Minimal residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells are present at levels undetectable by traditional microscopic examination (also called morphologic examination) of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as the next generation sequencing utilized by Adaptive’s clonoSEQ MRD Test, are needed for reliable detection of very low levels of MRD. Learn more at knowMRD.com.
About the clonoSEQ® Process
Adaptive’s clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than the other methods of MRD detection, such as ASO-PCR and flow cytometry.
Contacts
Adaptive Biotechnologies
April Falcone, 206-939-3835
media@adaptivebiotech.com